IRONWOOD PHARMACEUTICALS, INC. Repayments of Debt
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Repayments of Debt of $26.87 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2017-02-22
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2016-12-31 was $8.40M, a 97.07% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2016-09-30 was $7.16M, a 90.89% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2016-06-30 was $6.00M, a 145.54% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2016-03-31 was $5.30M, a 135.47% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for fiscal 2016 was $26.87M, a 111.36% increase from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for fiscal 2015 was $12.71M, a 993.04% increase from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for fiscal 2014 was $1.16M.
- IRONWOOD PHARMACEUTICALS, INC. repayments of debt for fiscal 2012 was $275.00K, a 5.77% increase from fiscal 2011.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2016-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $15.57M derived: sum of 2 quarters · filed 2017-02-22 | $21.57M derived: sum of 3 quarters · filed 2017-02-22 | $26.87M 10-K · filed 2017-02-22 |
| 2016-09-30 | $7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $13.16M derived: sum of 2 quarters · filed 2016-11-07 | $18.46M 10-Q · filed 2016-11-07 | $22.73M derived: sum of 4 quarters · filed 2017-02-22 |
| 2016-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $11.30M 10-Q · filed 2016-08-08 | $15.56M derived: sum of 3 quarters · filed 2017-02-22 | $19.32M derived: sum of 4 quarters · filed 2017-02-22 |
| 2016-03-31 | $5.30M 10-Q · filed 2016-05-10 | $9.56M derived: sum of 2 quarters · filed 2017-02-22 | $13.32M derived: sum of 3 quarters · filed 2017-02-22 | $15.76M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $8.02M derived: sum of 2 quarters · filed 2017-02-22 | $10.46M derived: sum of 3 quarters · filed 2017-02-22 | $12.71M 10-K · filed 2017-02-22 |
| 2015-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $6.20M derived: sum of 2 quarters · filed 2016-11-07 | $8.45M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $4.69M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $2.25M 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $1.16M 10-K · filed 2017-02-22 | |||
| 2012-12-31 | $275.00K 10-K · filed 2013-02-21 | |||
| 2011-12-31 | $260.00K 10-K · filed 2013-02-21 | |||
| 2010-12-31 | $1.96M 10-K · filed 2013-02-21 | |||
| 2009-12-31 | $1.25M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |